A K Wesa

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro
    Amy Wesa
    Department of Dermatology, University of Pittsburgh School of Medicine, PA 1513, USA
    J Immunother 30:75-82. 2007
  2. ncbi Killer dendritic cells: mechanisms of action and therapeutic implications for cancer
    A K Wesa
    Department of Dermatology, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Cell Death Differ 15:51-7. 2008
  3. ncbi Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists
    Amy K Wesa
    Department of Dermatology, University of Pittsburgh School ofMedicine, Pittsburgh, PA 15213, USA
    J Immunol 181:7721-7. 2008
  4. ncbi Increased production of pro-inflammatory cytokines and enhanced T cell responses after activation of human dendritic cells with IL-1 and CD40 ligand
    Amy Wesa
    Cancer Biology Program and Department of Immunology and Microbiology, Barbara Ann Karmanos Cancer Institute of Wayne State University, Detroit, USA
    BMC Immunol 3:14. 2002
  5. ncbi GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor
    Caroline Diveu
    INSERM U564, CHU d Angers, 49033 Angers, France
    J Biol Chem 278:49850-9. 2003
  6. ncbi 4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12
    Diego Laderach
    Department of Immunology and Microbiology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, USA
    Cell Immunol 226:37-44. 2003
  7. ncbi alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity
    Robbie B Mailliard
    Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213-1863, USA
    Cancer Res 64:5934-7. 2004
  8. ncbi Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors
    Kotaro Sasaki
    Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Res 67:6451-8. 2007
  9. ncbi Interleukin-12: biological properties and clinical application
    Michele Del Vecchio
    Medical Oncology Unit 2, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Italy
    Clin Cancer Res 13:4677-85. 2007

Collaborators

Detail Information

Publications9

  1. ncbi Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro
    Amy Wesa
    Department of Dermatology, University of Pittsburgh School of Medicine, PA 1513, USA
    J Immunother 30:75-82. 2007
    ..These results suggest that preexisting CD4+ T cell immunity to cancer is not relegated to Type-1 insufficiency and may be corrected via the application of DC1-based vaccination protocols...
  2. ncbi Killer dendritic cells: mechanisms of action and therapeutic implications for cancer
    A K Wesa
    Department of Dermatology, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Cell Death Differ 15:51-7. 2008
    ..In this review, we will critically examine the published record regarding KDC, their mechanism(s) of action, and then consider the potential integration of KDC into novel immunotherapies for patients with cancer...
  3. ncbi Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists
    Amy K Wesa
    Department of Dermatology, University of Pittsburgh School ofMedicine, Pittsburgh, PA 15213, USA
    J Immunol 181:7721-7. 2008
    ..These results suggest that strategies targeting the conditional proteasome-mediated destruction of tumor cell EphA2 may enable EphA2-specific CD8(+) T cells (of modest functional avidity) to realize improved therapeutic potential...
  4. ncbi Increased production of pro-inflammatory cytokines and enhanced T cell responses after activation of human dendritic cells with IL-1 and CD40 ligand
    Amy Wesa
    Cancer Biology Program and Department of Immunology and Microbiology, Barbara Ann Karmanos Cancer Institute of Wayne State University, Detroit, USA
    BMC Immunol 3:14. 2002
    ..The immuno-stimulatory capacity of such DC is otherwise not well-defined prompting further characterization of the effects of IL-1 and family members on DC activation in comparison with other pro-inflammatory stimuli...
  5. ncbi GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor
    Caroline Diveu
    INSERM U564, CHU d Angers, 49033 Angers, France
    J Biol Chem 278:49850-9. 2003
    ..Results indicated that association of GPL to the intracellular portions of gp130, or LIF receptor, allowed the signaling cascade...
  6. ncbi 4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12
    Diego Laderach
    Department of Immunology and Microbiology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, USA
    Cell Immunol 226:37-44. 2003
    ..Data illustrate reciprocal stimulations between T cells and APC via up-regulated receptor/ligands and production of key cytokines that consolidate cellular immune responses...
  7. ncbi alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity
    Robbie B Mailliard
    Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213-1863, USA
    Cancer Res 64:5934-7. 2004
    ..Serum-free generation of alphaDC1 allows, for the first time, the clinical application of DCs that combine the key three features important for their efficacy as anticancer vaccines...
  8. ncbi Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors
    Kotaro Sasaki
    Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Res 67:6451-8. 2007
    ....
  9. ncbi Interleukin-12: biological properties and clinical application
    Michele Del Vecchio
    Medical Oncology Unit 2, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Italy
    Clin Cancer Res 13:4677-85. 2007
    ..More effective application of this cytokine, and of newly identified IL-12 family members (IL-23 and IL-27), should be evaluated as therapeutic agents with considerable potential in cancer patients...